Soligenix (STU:DOA) Change In Receivables : €0.10 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Soligenix Change In Receivables?

Soligenix's change in receivables for the quarter that ended in Mar. 2024 was €0.07 Mil. It means Soligenix's Accounts Receivable declined by €0.07 Mil from Dec. 2023 to Mar. 2024 .

Soligenix's change in receivables for the fiscal year that ended in Dec. 2023 was €0.03 Mil. It means Soligenix's Accounts Receivable declined by €0.03 Mil from Dec. 2022 to Dec. 2023 .

Soligenix's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.11 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Soligenix's Days Sales Outstanding for the three months ended in Mar. 2024 was 91.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Soligenix's liquidation value for the three months ended in Mar. 2024 was €-0.10 Mil.

Soligenix Change In Receivables Historical Data

The historical data trend for Soligenix's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Change In Receivables Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.24

0.69

0.24

0.09

0.03

Soligenix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	0.09	0.04	-0.10	0.07

Soligenix Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.10 Mil.

Soligenix (STU:DOA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Soligenix's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.108	/	0.108	*	91
=	91.25

2. In Ben Graham's calculation of liquidation value, Soligenix's accounts receivable are only considered to be worth 75% of book value:

Soligenix's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.525	-	6.707	+	0.75 * 0.108	+	0.5 * 0
=	-0.10

Soligenix Change In Receivables Related Terms

Thank you for viewing the detailed overview of Soligenix's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (STU:DOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SNGX:USA

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines